Next Article in Journal
The ADORA2A TT Genotype Is Associated with Anti-Inflammatory Effects of Caffeine in Response to Resistance Exercise and Habitual Coffee Intake
Next Article in Special Issue
The Influence of Maternal Folate Status on Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis
Previous Article in Journal
Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1
Previous Article in Special Issue
Supports and Barriers to Lifestyle Interventions in Women with Gestational Diabetes Mellitus in Australia: A National Online Survey
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 7
10.3390/nu15071633
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of Probiotics on Glycemic Control and Metabolic Parameters in Gestational Diabetes Mellitus: Systematic Review and Meta-Analysis

by
Enav Yefet
1,2,*,
Liron Bar
1,
Ido Izhaki
3,
Rula Iskander
4,
Manal Massalha
4,5,
Johnny S. Younis
1,2 and
Zohar Nachum
4,5
1
Department of Obstetrics and Gynecology, Tzafon Medical Center, Poriya 1528001, Israel
2
Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel
3
Department of Evolutionary and Environmental Biology, University of Haifa, Haifa 3498838, Israel
4
Department of Obstetrics and Gynecology, Emek Medical Center, Afula 1834111, Israel
5
Rappaport Faculty of Medicine, Technion, Haifa 3200003, Israel
*
Author to whom correspondence should be addressed.
Nutrients 2023, 15(7), 1633; https://doi.org/10.3390/nu15071633
Submission received: 14 February 2023 / Revised: 25 March 2023 / Accepted: 27 March 2023 / Published: 28 March 2023
(This article belongs to the Special Issue Dietary Therapies and Lifestyle Modifications for Gestational Diabetes and Their Implications for Maternal and Offspring Health)
Browse Figures
Versions Notes

Abstract

:
Objectives: To assess the effects of probiotic supplements on glycemic control and metabolic parameters in women with gestational diabetes mellitus (GDM) by performing a systematic review and meta-analysis of randomized controlled trials. The primary outcome was glycemic control, i.e., serum glucose and insulin levels. Secondary outcomes were maternal weight gain, neonatal birth weight, and lipid parameters. Weighted mean difference (WMD) was used. Cochrane’s Q test of heterogeneity and I2 were used to assess heterogeneity. Results: Of the 843 papers retrieved, 14 (n = 854 women) met the inclusion criteria and were analyzed. When compared with placebo, women receiving probiotic supplements had significantly lower mean fasting serum glucose, fasting serum insulin, homeostatic model assessment for insulin resistance (HOMA-IR), triglycerides, total cholesterol, and VLDL levels. Decreased neonatal birth weight was witnessed in supplements containing Lactobacillus acidophilus. Conclusion: Probiotic supplements may improve glycemic control and lipid profile and reduce neonatal birth weight in women with GDM.

1. Introduction

Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications, and its prevalence is increasing worldwide [1]. It is associated with metabolic changes, such as obesity and insulin resistance [2,3]. Uncontrolled GDM is associated with adverse pregnancy outcomes and an increased risk for long-term morbidities in both the mother and child [4,5]. Therefore, adequate glycemic control in GDM has a major role in decreasing the incidence of complications such as macrosomia, shoulder dystocia, Caesarean section, preeclampsia, GDM recurrence, and future type 2 diabetes and dislipidemia [6,7,8].
GDM treatment includes diet and lifestyle interventions, oral anti-diabetes agents, and insulin injections if needed [9]. It has been hypothesized that some of the beneficial influences of lifestyle modifications might be due to alteration of the maternal gut microbiome [10]. Various factors affect the digestive tract microbiome, including host genetics, illness, antibiotics use, diet, weight loss, and pregnancy [2,11]. Recent evidence supported an association between the gut microbiome signature and insulin metabolism in GDM [2,3,10,12].
Although appropriate treatment of GDM cannot be stressed enough, good glycemic control is difficult to achieve. Among the reasons are low compliance for lifestyle behavior changes due to poor motivation, the need for six to seven daily painful blood tests, and multiple insulin injections (around four injections) that are performed repeatedly. The adverse effects of insulin and oral hypoglycemics, such as hypoglycemia and gastrointestinal symptoms, also limited the use of those medications, and sometimes those treatments are more dangerous than hyperglycemia to the mother and fetus.
Recently, probiotic treatments were investigated in the context of metabolic diseases. Probiotics have been defined by the World Health Organization (WHO) as live microorganisms that, when taken appropriately, provide health benefits to the host [2,11,13,14]. Recently, the consumption of probiotic supplements was widely investigated for their beneficial effects on treating metabolic diseases and infections [13,15]. Intake of probiotics is a safe alternative that has shown efficacy in regulating the human gut microbial composition and function by promoting favorable metabolic activity and normalizing the gut microbiota [16,17,18]. Supplementation with probiotics has improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus [17,19,20] and prevents GDM [21]. Yet, there are conflicting reports regarding its effectiveness in women with GDM [12,14,22,23,24,25,26,27,28,29,30,31]. The most common strains that were investigated to improve glycemic control in GDM were Lactobacillus acidophilus, Bifidobacterium bifidum, and Lactobacillus casei [12,14,22,23,25,26,27,28,29,30,31].
Our hypothesis was that probiotic supplements would improve glycemic control and lipid profile in women with GDM.
In the present study, we aimed to assess the effects of probiotic supplements on glycemic control and metabolic parameters in women with GDM by performing a systematic review and meta-analysis of randomized controlled trials.

2. Material and Methods

2.1. Eligibility Criteria, Information Sources, and Search Strategy

We performed a systematic review and meta-analysis of randomized controlled trials. The strategy search was followed the PICO (patient, intervention, comparison, and outcome) strategy. Embase, PubMed, Ovid-Medline, and Web of Science were searched using the following keywords: probiotics (probiotic/s, prebiotic/s, dietary fiber, synbiotic/s, lactobacillus, bifidobacterium, bifida) and gestational diabetes mellitus (GDM, diabetes, pregnancy/gravidarum and diabetes, pregnancy diabetes mellitus, pregnancy-induced and diabetes).
The search was restricted to English-language journals and full articles (no abstracts). All reference lists from the main reports and relevant reviews were manually searched for additional eligible publications. In addition, when clarifications were necessary or additional data were not shown in the published manuscript, the authors of the included studies were contacted. The search included all the available articles in the searched databases until 17 August 2022.
Manuscripts were included if they described a randomized controlled trial that compared probiotic treatment versus no or placebo treatment for glycemic control and metabolic parameters in women with GDM. We excluded studies on pregnant women without GDM, pregnant women with pre-GDM, studies that were not randomized controlled trials, or when there were no data on the primary outcomes.

2.2. Data Extraction

The credentials of the investigators were indicated in the list of authors. Two independent reviewers (LB and RI) appraised each full-text report for eligibility and extracted and tabulated all relevant data. Disagreement was settled by consensus among all authors. All procedures conformed to the guidelines for systematic review and meta-analysis of randomized controlled trial in epidemiology—PRISMA checklist [32].

2.3. Outcomes

The primary outcomes were levels of fasting glucose and insulin. Additional outcomes were maternal serum total cholesterol, high-density lipoproteins (HDL), LDL, very-low LDL (VLDL), triglycerides, homeostatic model assessment for insulin resistance (HOMA-IR) index, quantitative insulin-sensitivity check index (QUICKI), maternal weight gain, neonatal birth weight, large for gestational age fetus/macrosomia, and neonatal hypoglycemia. Adverse effects that might be related to the probiotics were also evaluated.
Each outcome was presented as weighted mean difference (WMD) with 95% confidence interval (CI) between the study and control groups. We performed sub-analyses in which we examined separately the effect of different strains of probiotic supplements on all the glycemic and metabolic parameters.

2.4. Data Synthesis and Assessment of the Risk of Bias

All reports were assigned a quality score based on the CONSORT guidelines [33]. The maximum score was 25.
Meta-analyses and review articles are exempt from the institutional review board approval in our institutions. OpenMeta Analyst software for Windows was used to perform the meta-analyses. Cochrane Q tests and the I2 (inconsistency) statistics were used to assess the heterogeneity of analyses. The random-effects model was used as a standard in determining heterogeneity between studies. The I2 values are expressed in percentages. Heterogeneity was classified as low, moderate, and high, with I2 ranging 0–25%, 25–50%, and >50%, respectively. The risk of bias was addressed by Egger’s statistics and funnel plots, and prepared using MedCalc statistical software. p < 0.05 was considered statistically significant.
Trial registration: This study was registered at PROSPERO (CRD42021233502).

3. Results

3.1. Study Selection

The study selection process is shown in Figure 1. Of the 843 articles identified, 14 publications were deemed eligible according to the inclusion criteria [12,14,22,23,24,25,26,27,28,29,30,31,34,35].

3.2. Study Characteristics

Study summaries are presented in Table 1. Overall, 430 women received probiotic supplements, and 424 women were in control groups, which, in all cases, included placebo treatment. Treatment duration ranged between four weeks and until delivery. Various probiotic formulas were used. Specific adverse effects were predefined in only one study [30]. Quality scores for all studies were high. Egger’s test and a funnel plot for each outcome are presented in Table 2 and Supplement S2, respectively. Publication bias is possible in favor of the effect of probiotic towards the glucose, insulin and HOMA-IR variables according to the Egger’s test (p < 0.05; Table 2) and the funnel plots (Supplement S2).

3.3. Synthesis of Results

Forest plots of the study outcomes are presented in Figure 2, Figure 3, Figure 4 and Figure 5. When compared with the placebo groups, probiotics administration was associated with a reduction in the levels of fasting plasma glucose (WMD −2.1 mg/dL 95% CI [(−4.0)–(−0.3)]; Figure 2) and fasting plasma insulin (WMD −2.4 μIU/mL 95% CI [(−3.6)–(−1.2)]; Figure 3A), HOMA-IR (WMD −0.6 95% CI [(−0.8)–(−0.3)]; Figure 3B), triglycerides (WMD −17.7 mg/dL 95% CI [(−29.7)–(−5.8)]; Figure 4A), total cholesterol (WMD −10.7 mg/dL 95% CI [(−18.8)–(−2.6)]; Figure 4B), and VLDL (WMD −4.7 mg/dL 95% CI [(−7.5)–(−1.8)]; Figure 4E), alongside higher QUICKI (Figure 3C). There was no difference between cohorts in neonatal birth weight (Figure 5A) or maternal weight gain (Figure 5B), and LDL (Figure 4C) or HDL (Figure 4D).
We performed sub-analyses in which we examined separately the effect on metabolic parameters of the three most common bacterial strains used in the probiotic formulas: Lactobacillus acidophilus, Bifidobacterium bifidum, and Lactobacillus casei (Table 3). All bacterial strains had favorable effects on various metabolic outcomes. Lactobacillus acidophilus positively affected eight parameters, including a decrease in neonatal birth weight. Bifidobacterium bifidum positively affected eight parameters as well and Lactobacillus casei positively affected five parameters (Table 3). There were no data regarding large for gestational age fetus/macrosomia and neonatal hypoglycemia. No serious adverse effects were reported for the probiotic treatment.

4. Discussion

4.1. Main Findings

In the present study, we aimed to assess the effects of probiotic supplements on glycemic control and metabolic parameters in women with GDM by performing a systematic review and meta-analysis of randomized controlled trials.
It was found that probiotic supplements improved glycemic control, insulin resistance, and lipid profile. Lactobacillus acidophilus, Bifidobacterium bifidum, and Lactobacillus casei, which were the most common bacterial strains used in the probiotic formulas, had favorable effects on various metabolic outcomes when assessed separately. Of interest, studies that used Lactobacillus acidophilus demonstrated lower neonatal birth weight in the probiotic group compared with controls.

4.2. Comparison with Existing Literature

GDM complicates 4–12% of pregnancies [1]. Adequate glycemic control is highly important during pregnancy, since uncontrolled GDM was associated with severe maternal and neonatal morbidities [4,5,36]. Adequate glycemic control is also important to prevent long-term maternal complications. In a mean follow-up time of 15.8 ± 5.1 years, it was found that inadequate glycemic control during pregnancies with GDM was an independent risk factor for future type 2 diabetes mellitus and dyslipidemia [7]. In addition, high post-prandial glucose levels were associated with increased risk for GDM recurrence in the next pregnancy [37].
The treatment in GDM is multidisciplinary and includes dietary and lifestyle changes such as regular exercise, as well as drug administration of oral agents or insulin in more resistant cases. Yet, those treatments are time- and effort-consuming and anti-diabetic medications have potential life-threatening adverse effects such as maternal hypoglycemia following insulin or glibenclamide use. Thus, more convenient and safe methods to treat GDM were searched for.
Probiotics have shown an efficacy in manipulating the human gut microbial composition and function to reduce the adverse metabolic effects associated with pathogenic microbial colonization [16,17]. Probiotic supplements have been shown to improve metabolism by increasing host insulin sensitivity, cholesterol metabolism, and beneficial effects on the immune system [18]. Indeed, positive effects were noticed when the use of probiotics was studied in non-pregnant individuals with diabetes mellitus [17]. Administration of Lactobacillus acidophilus reduced fasting glucose and hemoglobin A1C levels [19] and preserved insulin sensitivity [20] in those patients.
In pregnancy, probiotic supplements were tested in the prevention of GDM [21]. In the study of Luoto et al., the aim of the study was to determine the safety and efficacy of perinatal probiotic-supplemented dietary counseling by evaluating pregnancy outcome and fetal and infant growth during the 24-month follow-up. In total, 256 women were randomized at their first trimester of pregnancy into control and a dietary intervention groups. The intervention group received intensive dietary counseling provided by a nutritionist and were further randomized, double-blind, to receive probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12) or placebo. The probiotic intervention significantly reduced the frequency of GDM from 34% and 36% to 13% in the control, placebo and probiotic groups, respectively. The safety of this approach was attested by the normal duration of pregnancies with no adverse events in mothers or children, and no significant differences in prenatal or postnatal growth rates among the study groups were detected [21]. In another randomized controlled clinical trial, 70 primigravida pregnant women with singleton pregnancy at their third trimester were randomly allocated to consume 200 g per day of conventional (n = 33) or probiotic yoghurt (n = 37) for 9 weeks. The probiotic yoghurt consisted of Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus LA5, and Bifidobacterium animalis BB12. Fasting blood samples were taken at baseline and after a 9-week intervention to measure fasting plasma glucose and serum insulin levels. HOMA-IR was used to calculate insulin resistance score. When comparing the changes from baseline to 9 weeks of consumption of the two yogurts, the elevation in insulin resistance was milder in the probiotic group compared with the conventional group, as suggested by the lower elevation in serum insulin levels and decrease in HOMA-IR index [38]. On the contrary, in two studies that used Lactobacillus salivarius, no effect on glucose metabolism was noticed, neither in obese pregnant woman [39] nor women with GDM [24]. Notably, both studies used Lactobacillus salivarius, while the studies that demonstrated a positive effect used different strains. In addition, low gastric and intestinal motility in pregnancy might require a higher dose of probiotic to achieve an effect.
In our study, sub-analysis of different probiotic strains yielded different metabolic effects. These results stress the fact that probiotic supplements are a heterogenic group consisting of various bacteria, and each one can act differently on glucose and metabolic pathways. In future studies there should be more focus on the effect of each bacterial strain in order to characterize the appropriate supplement for each metabolic disorder. Such a strategy will be able to achieve a more robust effect while avoiding false-negative results that can be found following the integration of various kinds of probiotic supplements.
In pregnant women, the intestinal bacterial composition has been implicated in alterations in insulin, c-peptide, HOMA-IR, and hemoglobin A1C levels, as well as low-grade inflammatory responses, which lead to GDM manifestations [40,41,42]. Maternal insulin resistance leading to hyperglycemia and fetal hyperinsulinemia has been suggested to underlie fetal overgrowth and macrosomia [43] and increased maternal lipid levels regardless of glycemic control [44].
Probiotic supplements were suggested to improve glucose, insulin, and lipid metabolism and decrease inflammatory response, reducing the risk for GDM and unfavorable pregnancy outcomes [45,46]. The mechanisms by which probiotic supplements alter glucose metabolism include the production of short-chain fatty acids, which were found to (1) regulate the production of hormones such as leptin and grehlin [47], affecting energy intake and expenditure, (2) increase the intestinal expression of peptide YY and glucagon-like peptide-1 (GLP-1) hormones, which act to increase insulin sensitivity [48], and (3) enhance the production of glucagon-like peptide-2 (GLP-2), which reduces inflammation [49,50]. Probiotic administration in women with GDM was also reported to reduce inflammatory markers, such as high-sensitivity C-reactive protein, tumor necrosis factor-α, and interleukin-6 [14,50].

4.3. Strengths, Limitations and Suggestions

The strengths of this meta-analysis lay in its incorporation of 14 high-quality, randomized, placebo-controlled trials with a large sample size of 854 women, as well as the investigation of various metabolic parameters that are known to affect pregnancy outcomes in GDM. Its limitations included inter-study heterogeneity concerning the type of probiotic supplement, the effective dose range and duration of treatment, and a possible publication bias toward the positive effect of the probiotic supplements on GDM parameters. Another limitation was that only fasting glucose was evaluated but not mean daily glucose or postprandial glucose levels, which were demonstrated to better predict pregnancy complications in GDM [36]. Future studies should examine the effect of probiotic supplements on the daily glucose charts, including pre-prandial, postprandial, and mean daily glucose values, since those are used to evaluate glycemic control and respond to treatment in clinical settings. Neonatal outcomes that are associated with GDM should also be evaluated in a more comprehensive manner.

5. Conclusions

Probiotic supplements may improve glycemic control and lipid profile and reduce neonatal birth weight in women with GDM.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu15071633/s1.

Author Contributions

E.Y., L.B., I.I., R.I., J.S.Y., M.M. and Z.N. all made substantial contributions to the conceptualization and design of the study. L.B. and R.I. reviewed each full-text report for eligibility and extracted and tabulated all relevant data. I.I. analyzed the data. E.Y. and Z.N. drafted the article. L.B., I.I., R.I. and J.S.Y. performed critical reviews of the article content. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable. Meta-analyses and review articles are exempt from IRB approval in our institutions.

Data Availability Statement

No new data were created in this meta-analysis.

Acknowledgments

We would like to thank Tal Kaminski-Rosenberg and Leora Mauda, The Alfred Goldschmidt Medical Sciences Library, Rappaport Faculty of Medicine, and Technion—Israel Institute of Technology, for their assistance in the literature search.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Schneider, S.; Bock, C.; Wetzel, M.; Maul, H.; Loerbroks, A. The prevalence of gestational diabetes in advanced economies. J. Perinat. Med. 2012, 40, 511–520. [Google Scholar] [CrossRef] [PubMed]
  2. Dallanora, S.; Medeiros, d.S.; Deon, R.G.; Tracey, C.A.; Freitas-Vilela, A.A.; Wurdig Roesch, L.F.; Mendes, R.H. Do probiotics effectively ameliorate glycemic control during gestational diabetes? A systematic review. Arch. Gynecol. Obstet. 2018, 298, 477–485. [Google Scholar] [CrossRef] [PubMed]
  3. Hasain, Z.; Mokhtar, N.M.; Kamaruddin, N.A.; Mohamed Ismail, N.A.; Razalli, N.H.; Gnanou, J.V.; Raja Ali, R.A. Gut Microbiota and Gestational Diabetes Mellitus: A Review of Host-Gut Microbiota Interactions and Their Therapeutic Potential. Front. Cell. Infect. Microbiol. 2020, 10, 188. [Google Scholar] [CrossRef] [PubMed]
  4. Poomalar, G.K. Changing trends in management of gestational diabetes mellitus. World J. Diabetes 2015, 6, 284–295. [Google Scholar] [CrossRef]
  5. Chiefari, E.; Arcidiacono, B.; Foti, D.; Brunetti, A. Gestational diabetes mellitus: An updated overview. J. Endocrinol. Investig. 2017, 40, 899–909. [Google Scholar] [CrossRef] [PubMed]
  6. Garrison, A. Screening, diagnosis, and management of gestational diabetes mellitus. Am. Fam. Physician 2015, 91, 460–467. [Google Scholar]
  7. Yefet, E.; Schwartz, N.; Sliman, B.; Ishay, A.; Nachum, Z. Good glycemic control of gestational diabetes mellitus is associated with the attenuation of future maternal cardiovascular risk: A retrospective cohort study. Cardiovasc. Diabetol. 2019, 18, 75. [Google Scholar] [CrossRef] [Green Version]
  8. Schwartz, N.; Green, M.S.; Yefet, E.; Nachum, Z. Modifiable risk factors for gestational diabetes recurrence. Endocrine 2016, 54, 714–722. [Google Scholar] [CrossRef]
  9. Mack, L.R.; Tomich, P.G. Gestational Diabetes: Diagnosis, Classification, and Clinical Care. Obstet. Gynecol. Clin. N. Am. 2017, 44, 207–217. [Google Scholar] [CrossRef]
  10. Ferrocino, I.; Ponzo, V.; Gambino, R.; Zarovska, A.; Leone, F.; Monzeglio, C.; Goitre, I.; Rosato, R.; Romano, A.; Grassi, G.; et al. Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM). Sci. Rep. 2018, 8, 12216. [Google Scholar] [CrossRef]
  11. Taylor, B.L.; Woodfall, G.E.; Sheedy, K.E.; O’Riley, M.L.; Rainbow, K.A.; Bramwell, E.L.; Kellow, N.J. Effect of Probiotics on Metabolic Outcomes in Pregnant Women with Gestational Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2017, 9, 461. [Google Scholar] [CrossRef] [Green Version]
  12. Karamali, M.; Dadkhah, F.; Sadrkhanlou, M.; Jamilian, M.; Ahmadi, S.; Tajabadi-Ebrahimi, M.; Jafari, P.; Asemi, Z. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Metab. 2016, 42, 234–241. [Google Scholar] [CrossRef] [PubMed]
  13. Han, M.-M.; Sun, J.-F.; Su, X.-H.; Peng, Y.-F.; Goyal, H.; Wu, C.-H.; Zhu, X.-Y.; Li, L. Probiotics improve glucose and lipid metabolism in pregnant women: A meta-analysis. Ann. Transl. Med. 2019, 7, 99. [Google Scholar] [CrossRef] [PubMed]
  14. Jafarnejad, S.; Saremi, S.; Jafarnejad, F.; Arab, A. Effects of a Multispecies Probiotic Mixture on Glycemic Control and Inflammatory Status in Women with Gestational Diabetes: A Randomized Controlled Clinical Trial. J. Nutr. Metab. 2016, 2016, 5190846. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Yefet, E.; Colodner, R.; Strauss, M.; Letova, Y.G.Z.; Nachum, Z. A Randomized Controlled Open Label Crossover Trial to Study Vaginal Colonization of Orally Administered Lactobacillus Reuteri RC-14 and Rhamnosus GR-1 in Pregnant Women at High Risk for Preterm Labor. Nutrients 2020, 12, 1141. [Google Scholar] [CrossRef] [Green Version]
  16. Clarke, S.F.; Murphy, E.F.; Nilaweera, K.; Ross, P.R.; Shanahan, F.; O’Toole, P.W.; Cotter, P.D. The gut microbiota and its relationship to diet and obesity: New insights. Gut Microbes 2012, 3, 186–202. [Google Scholar] [CrossRef]
  17. Gomes, A.C.; Bueno, A.A.; de Souza, R.G.; Mota, J.F. Gut microbiota, probiotics and diabetes. Nutr. J. 2014, 13, 60. [Google Scholar] [CrossRef] [Green Version]
  18. Barrett, H.L.; Callaway, L.K.; Nitert, M.D. Probiotics: A potential role in the prevention of gestational diabetes? Acta Diabetol. 2012, 49, S1–S13. [Google Scholar] [CrossRef]
  19. Ejtahed, H.S.; Mohtadi-Nia, J.; Homayouni-Rad, A.; Niafar, M.; Asghari-Jafarabadi, M.; Mofid, V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012, 28, 539–543. [Google Scholar] [CrossRef]
  20. Andreasen, A.S.; Larsen, N.; Pedersen-Skovsgaard, T.; Berg, R.M.G.; Møller, K.; Svendsen, K.D.; Jakobsen, M.; Pedersen, B.K. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br. J. Nutr. 2010, 104, 1831–1838. [Google Scholar] [CrossRef] [Green Version]
  21. Luoto, R.; Laitinen, K.; Nermes, M.; Isolauri, E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: A double-blind, placebo-controlled study. Br. J. Nutr. 2010, 103, 1792–1799. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Dolatkhah, N.; Hajifaraji, M.; Abbasalizadeh, F.; Aghamohammadzadeh, N.; Mehrabi, Y.; Abbasi, M.M. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J. Health Popul. Nutr. 2015, 33, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Sahhaf, E.F.; Homayouni, R.A.; Mosen, M.; Abbasalizadeh, F.; Tabrizi, A.; Khalili, L. Effect of L. acidophilus and B. lactis on blood glucose in women with gestational diabetes mellitus: A randomized placebo-controlled trial. Diabetol. Metab. Syndr. 2019, 11, 75. [Google Scholar] [CrossRef] [PubMed]
  24. Lindsay, K.L.; Brennan, L.; Kennelly, M.A.; Maguire, O.C.; Smith, T.; Curran, S.; Coffey, M.; Foley, M.E.; Hatunic, M.; Shanahan, F. Impact of probiotics in women with gestational diabetes mellitus on metabolic health: A randomized controlled trial. Am. J. Obstet. Gynecol. 2015, 212, 496.e1–496.e11. [Google Scholar] [CrossRef]
  25. Ahmadi, S.; Jamilian, M.; Tajabadi-Ebrahimi, M.; Jafari, P.; Asemi, Z. The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: A randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 2016, 116, 1394–1401. [Google Scholar] [CrossRef] [Green Version]
  26. Nabhani, Z.; Hezaveh, S.J.G.; Razmpoosh, E.; Asghari-Jafarabadi, M.; Gargari, B.P. The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: A randomized double blind placebo controlled clinical trial. Diabetes Res. Clin. Pract. 2018, 138, 149–157. [Google Scholar] [CrossRef]
  27. Badehnoosh, B.; Karamali, M.; Zarrati, M.; Jamilian, M.; Bahmani, F.; Tajabadi-Ebrahimi, M.; Jafari, P.; Rahmani, E.; Asemi, Z. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J. Matern. Fetal Neonatal Med. 2018, 31, 1128–1136. [Google Scholar] [CrossRef] [Green Version]
  28. Babadi, M.; Khorshidi, A.; Aghadavood, E.; Samimi, M.; Kavossian, E.; Bahmani, F.; Mafi, A.; Shafabakhsh, R.; Satari, M.; Asemi, Z. The Effects of Probiotic Supplementation on Genetic and Metabolic Profiles in Patients with Gestational Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial. Probiotics Antimicrob. Proteins 2018, 11, 1227–1235. [Google Scholar] [CrossRef]
  29. Karamali, M.; Nasiri, N.; Taghavi, S.N.; Jamilian, M.; Bahmani, F.; Tajabadi-Ebrahimi, M.; Asemi, Z. The Effects of Synbiotic Supplementation on Pregnancy Outcomes in Gestational Diabetes. Probiotics Antimicrob. Proteins 2018, 10, 496–503. [Google Scholar] [CrossRef]
  30. Kijmanawat, A.; Panburana, P.; Reutrakul, S.; Tangshewinsirikul, C. Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial. J. Diabetes Investig. 2019, 10, 163–170. [Google Scholar] [CrossRef] [Green Version]
  31. Jamilian, M.; Amirani, E.; Asemi, Z. The effects of vitamin D and probiotic co-supplementation on glucose homeostasis, inflammation, oxidative stress and pregnancy outcomes in gestational diabetes: A randomized, double-blind, placebo-controlled trial. Clin. Nutr. 2019, 38, 2098–2105. [Google Scholar] [CrossRef] [PubMed]
  32. PRISMA-P Group; Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement. Syst. Rev. 2015, 4, 1. [Google Scholar] [CrossRef] [Green Version]
  33. Vandenbroucke, J.P.; von Elm, E.; Altman, D.G.; Gotzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS Med. 2007, 4, e297. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Pellonpera, O.; Mokkala, K.; Houttu, N.; Vahlberg, T.; Koivuniemi, E.; Tertti, K.; Rönnemaa, T.; Laitinen, K. Efficacy of Fish Oil and/or Probiotic Intervention on the Incidence of Gestational Diabetes Mellitus in an At-Risk Group of Overweight and Obese Women: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Diabetes Care 2019, 42, 1009–1017. [Google Scholar] [CrossRef]
  35. Amirani, E.; Asemi, Z.; Taghizadeh, M. The effects of selenium plus probiotics supplementation on glycemic status and serum lipoproteins in patients with gestational diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Clin. Nutr. ESPEN 2022, 48, 56–62. [Google Scholar] [CrossRef] [PubMed]
  36. de Veciana, M.; Major, C.A.; Morgan, M.A.; Asrat, T.; Toohey, J.S.; Lien, J.M.; Evans, A.T. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N. Engl. J. Med. 1995, 333, 1237–1241. [Google Scholar] [CrossRef]
  37. Schwartz, N.; Green, M.S.; Yefet, E.; Nachum, Z. Postprandial glycemic control during gestational diabetes pregnancy predicts the risk of recurrence. Sci. Rep. 2018, 8, 6350. [Google Scholar] [CrossRef] [Green Version]
  38. Asemi, Z.; Samimi, M.; Tabassi, Z.; Naghibi, R.M.; Rahimi, F.A.; Khorammian, H.; Esmaillzadeh, A. Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: A randomized controlled trial. Eur. J. Clin. Nutr. 2013, 67, 71–74. [Google Scholar]
  39. Lindsay, K.L.; Kennelly, M.; Culliton, M.; Smith, T.; Maguire, O.C.; Shanahan, F.; Brennan, L.; McAuliffe, F.M. Probiotics in obese pregnancy do not reduce maternal fasting glucose: A double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). Am. J. Clin. Nutr. 2014, 99, 1432–1439. [Google Scholar] [CrossRef] [Green Version]
  40. Neri, C.; Serafino, E.; Morlando, M.; Familiari, A. Microbiome and Gestational Diabetes: Interactions with Pregnancy Outcome and Long-Term Infant Health. J. Diabetes Res. 2021, 2021, 9994734. [Google Scholar] [CrossRef]
  41. Gohir, W.; Whelan, F.J.; Surette, M.G.; Moore, C.; Schertzer, J.D.; Sloboda, D.M. Pregnancy-related changes in the maternal gut microbiota are dependent upon the mother’s periconceptional diet. Gut Microbes 2015, 6, 310–320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Vrachnis, N.; Belitsos, P.; Sifakis, S.; Dafopoulos, K.; Siristatidis, C.; Pappa, K.I.; Iliodromiti, Z. Role of Adipokines and Other Inflammatory Mediators in Gestational Diabetes Mellitus and Previous Gestational Diabetes Mellitus. Int. J. Endocrinol. 2012, 2012, 549748. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Schwartz, R.; Gruppuso, P.A.; Petzold, K.; Brambilla, D.; Hiilesmaa, V.; Teramo, K.A. Hyperinsulinemia and Macrosomia in the Fetus of the Diabetic Mother. Diabetes Care 1994, 17, 640–648. [Google Scholar] [CrossRef]
  44. Catalano, P.M.; Hauguel-De Mouzon, S. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? Am. J. Obstet. Gynecol. 2011, 204, 479–487. [Google Scholar] [CrossRef]
  45. Sekirov, I.; Russell, S.L.; Antunes, L.C.; Finlay, B.B. Gut microbiota in health and disease. Physiol. Rev. 2010, 90, 859–904. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. Ann. Rev. Immunol. 2011, 29, 415–445. [Google Scholar] [CrossRef] [Green Version]
  47. Kellow, N.J.; Coughlan, M.T.; Reid, C.M. Metabolic benefits of dietary prebiotics in human subjects: A systematic review of randomised controlled trials. Br. J. Nutr. 2014, 111, 1147–1161. [Google Scholar] [CrossRef]
  48. Tilg, H.; Moschen, A.R. Food, immunity, and the microbiome. Gastroenterology 2015, 148, 1107–1119. [Google Scholar] [CrossRef]
  49. Jayashree, B.; Bibin, Y.S.; Prabhu, D.; Shanthirani, C.S.; Gokulakrishnan, K.; Lakshmi, B.S.; Mohan, V.; Balasubramanyam, M. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol. Cell. Biochem. 2014, 388, 203–210. [Google Scholar] [CrossRef]
  50. Kamińska, K.; Stenclik, D.; Błażejewska, W.; Bogdański, P.; Moszak, M. Probiotics in the Prevention and Treatment of Gestational Diabetes Mellitus (GDM): A Review. Nutrients 2022, 14, 4303. [Google Scholar] [CrossRef]
Nutrients 15 01633 g001 550
Figure 1. CONSORT flow of identified and appraised publications. RCT, randomized controlled trial.
Figure 1. CONSORT flow of identified and appraised publications. RCT, randomized controlled trial.
Nutrients 15 01633 g001
Nutrients 15 01633 g002 550
Figure 2. Forest plot of probiotic treatment versus placebo and fasting plasma glucose levels (mg/dL). C.I.: confidence interval [12,14,22,23,24,25,26,27,28,30,31,34,35].
Figure 2. Forest plot of probiotic treatment versus placebo and fasting plasma glucose levels (mg/dL). C.I.: confidence interval [12,14,22,23,24,25,26,27,28,30,31,34,35].
Nutrients 15 01633 g002
Nutrients 15 01633 g003 550
Figure 3. Forest plot of probiotic treatment versus placebo and insulin resistance parameters. (A) insulin (µIU/mL) [12,14,22,24,25,28,30,31,34,35], (B) homeostatic model assessment for insulin resistance (HOMA-IR) [12,14,22,24,25,26,28,30,31,34,35], and (C) the quantitative insulin-sensitivity check index (QUICKI). C.I.: confidence interval [12,22,25,26,28,31,34,35].
Figure 3. Forest plot of probiotic treatment versus placebo and insulin resistance parameters. (A) insulin (µIU/mL) [12,14,22,24,25,28,30,31,34,35], (B) homeostatic model assessment for insulin resistance (HOMA-IR) [12,14,22,24,25,26,28,30,31,34,35], and (C) the quantitative insulin-sensitivity check index (QUICKI). C.I.: confidence interval [12,22,25,26,28,31,34,35].
Nutrients 15 01633 g003
Nutrients 15 01633 g004 550
Figure 4. Forest plot of probiotic treatment versus placebo and lipid profile. (A) Triglycerides (mg/dL) [12,24,25,26,28,31,35], (B) total cholesterol (mg/dL) [12,24,25,26,28,31,35], (C) low-density lipoproteins (mg/dL) [12,24,25,26,28,31,35], (D) high-density lipoproteins (mg/dL) [12,24,25,26,28,31,35], and (E) very-low-density lipoproteins (mg/dL). C.I.: confidence interval [12,25,28,31,35].
Figure 4. Forest plot of probiotic treatment versus placebo and lipid profile. (A) Triglycerides (mg/dL) [12,24,25,26,28,31,35], (B) total cholesterol (mg/dL) [12,24,25,26,28,31,35], (C) low-density lipoproteins (mg/dL) [12,24,25,26,28,31,35], (D) high-density lipoproteins (mg/dL) [12,24,25,26,28,31,35], and (E) very-low-density lipoproteins (mg/dL). C.I.: confidence interval [12,25,28,31,35].
Nutrients 15 01633 g004
Nutrients 15 01633 g005 550
Figure 5. Forest plot of probiotic treatment versus placebo and neonatal birth weight (g) (A) and maternal weight gain (kg) [23,24,27,29,30,31,34] (B) C.I.: confidence interval [12,14,22,24,25,26,27,28,29,30,31,34,35].
Figure 5. Forest plot of probiotic treatment versus placebo and neonatal birth weight (g) (A) and maternal weight gain (kg) [23,24,27,29,30,31,34] (B) C.I.: confidence interval [12,14,22,24,25,26,27,28,29,30,31,34,35].
Nutrients 15 01633 g005
Table
Table 1. Summary of included studies.
Table 1. Summary of included studies.
First Author, YearCountryNumber of SubjectsProbiotic InterventionProbiotic Dose/DayIntervention PeriodPrimary OutcomeResultsQuality Score *
Dolatkhah et al., 2015 [22]TurkeyProbiotics n = 29 placebo n = 27Lactobacillus acidophilus LA-5, Bifidobacterium BB-12, Streptococcus thermophilus STY-31 and Lactobacillus delbrueckii bulgaricus LBY-274 biocap
>4 × 109 CFU		8 weeksWeight gain and glucose metabolismDecrease in FPG24
Lindsay et al., 2015 [24]IrelandProbiotics n = 48 placebo n = 52Lactobacillus salivarius UCC118100 mg of
Lactobacillus salivarius UCC118 at a
target dose of 109 CFU		8 weeksFasting glucoseNo impact on glycemic control among GDM patients25
Karamali et al., 2016 [12]IranProbiotics n = 30 Placebo n = 30L. acidophilus, L. casei and
B. bifidum strains		2 × 109 CFU/g each6 weeksGlucose homoeostasis parametersDecrease in FPG and serum insulin levels25
Jafarnejad et al., 2016 [14]IranProbiotics n = 37 Placebo n = 35VSL#3 (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus)112.5 × 109 CFU8 weeksGlycemic control and inflammatory statusFPG, HbA1c, HOMA-IR, and insulin levels remained unchanged22
Ahmadi et al., 2016 [25]IranProbiotics n = 35 Placebo n = 35Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum plus 0.8 g inulin2 × 109 colony-forming units/g each6 weeksInsulin metabolismDecrease in serum insulin levels25
Nabhani et al., 2018 [26]IranProbiotics n = 45 Placebo n = 45Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus gasseri500 mg of Lactobacillus probiotic strains
consisting of L. acidophilus (5 × 1010 CFU/g), L. plantarum (1.5 × 1010 CFU/g), L. fermentum
(7 × 109 CFU/g), L. gasseri (2 × 1010 CFU/g)		6 weeksGlucose homoeostasis parametersNo effect on FPG and insulin resistance/sensitivity indices25
Badehnoosh et al., 2018 [27]IranProbiotics n = 30 Placebo n = 30Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum2 × 109 CFU/g each6 weeksInflammatory markersDecrease in FPG, no effect on pregnancy outcomes24
Karamali et al., 2018 [29]IranProbiotics n = 30 Placebo n = 30Lactobacillus acidophilus (2 × 109 CFU/g), Lactobacillus casei (2 × 109 CFU/g) and Bifidobacterium bifidum (2 × 109 CFU/g) strains plus 800 mg inulin2 × 109 CFU/g each6 weeksInflammatory markersNo effect on birth weight23
Babadi et al., 2019 [28]IranProbiotics n = 24 Placebo n = 24Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum2 × 109 CFU/g each6 weeksGene expression of PPAR-γDecrease in FPG, serum insulin levels and insulin resistance; increased insulin sensitivity23
Sahhaf Ebrahimi et al., 2019 [23]IranProbiotics n = 42 Placebo n = 42Probiotic yoghurt containing Lactobacillus acidophilus and Bifidobacterium lactis300 g/day of probiotic yoghurt (contained
106
Lactobacillus acidophilus and Bifidobacterium lactis		8 weeksGlycemic parametersDecrease in FPG and HbA1c, lower birth weight and fewer macrosome neonates in the probiotic group24
Kijmanawat et al., 2019 [30]ThailandProbiotics n = 28 Placebo n = 29Lactobacillus acidophilus and Bifidobacterium bifidum1 × 109 CFU/g each4 weeksGlycemic controlDecrease in FPG and serum insulin levels, and increased insulin sensitivity25
Jamilian et al., 2019 [31]IranProbiotics n = 29 Placebo n = 28Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus fermentum8 × 109 CFU/day6 weeksInsulin metabolismDecrease in FPG and serum insulin levels25
Pellonpera et al., 2019 [34]FinlandProbiotics n = 27 Placebo n = 22Lactobacillus
rhamnosus
and Bifidobacterium
animalis ssp. lactis		1 × 1010 CFU eachFrom the first study visit, throughout the pregnancy, and until 6 months postpartumThe incidence
of GDM		No difference in FPG, insulin resistance, maternal weight gain and neonatal birth weight24
Amirani et al., 2022 [35]IranProbiotics n = 26 Placebo n = 25Lactobacillus acidophilus, Bifidobacterium bifidum,
Bifidobacterium lactis Bifidobacterium longum
Additionally, selenium		2 × 109 CFU/day each6 weeksInsulin metabolismReduced fasting glucose, insulin concentrations, insulin resistance, triglycerides, total cholesterol, and low-density lipoprotein (LDL) cholesterol24
* Quality scores were based on the CONSORT checklist. The maximum score was 25. Abbreviations: CFU, colony-forming units; GDM, gestational diabetes mellitus, FPG, fasting plasma glucose; PPAR-γ, peroxisome proliferator-activated receptor gamma.
Table
Table 2. Egger’s test for asymmetry.
Table 2. Egger’s test for asymmetry.
Outcomep Value
FPG0.03
Fasting plasma Insulin0.048
Neonatal birth weight0.95
HOMA-IR0.005
QUICKI0.57
Triglycerides0.24
VLDL cholesterol0.052
Total cholesterol0.37
LDL cholesterol0.43
HDL cholesterol0.96
Maternal weight gain0.93
Abbreviations: FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment for insulin resistance; HDL, high-density lipoproteins; LDL, low-density lipoproteins; QUICKI, the quantitative insulin sensitivity check index; VLDL, very-low-density lipoproteins.
Table
Table 3. Sub-analysis of metabolic effects according to specific bacteria.
Table 3. Sub-analysis of metabolic effects according to specific bacteria.
FPG (mg/dL)Fasting Insulin (µIU/mL)Neonatal Birth Weight (g)HOMA-IRQUICKITG (mg/dL)VLDL (mg/dL)Total Cholesterol (mg/dL)
Lactobacillus acidophilus−2.8
[(−4.7)–(−0.9)]		−2.7
[(−4.0)–(−1.3)]		−141
[(−262)–(−19)]		−0.6
[(−0.9)–(−0.4)]		0.008
[0.002–0.01]		−21
[(−34)–(−8)]		−4.7
[(−7.5)–(−1.8)]		−12
[(−22)–(−1.7)]
Bifidobacterium
bifidum		−3.7
[(−5.5)–(−2.0)]		−2.4
[(−3.8)–(−1.1)]		−88
[(−204)–(27)]		−0.7
[(−1.0)–(−0.4)]		0.008
[0.002–0.015]		−23
[(−38)–(−9)]		−4.7
[(−7.5)–(−1.8)]		−16
[(−26)–(−6)]
Lactobacillus casei−2.2
[(−4.5)–(0.1)]		−4.5
[(−7.9)–(−1.2)]		−153
[(−306)–(1)]		−1.1
[(−1.6)–(−0.6)]		0.006
[(−0.002)–0.013]		−29
[(−54)–(−4)]		−5.8
[(−10.8)–(−0.8)]		−21
[(−34)–(−8)]
Maternal Weight Gain (Kg)HDL (mg/dL)LDL (mg/dL)
Lactobacillus acidophilus−0.006 [(−0.1)–(0.1)]−1.2 [(−5.5)–(3.0)]−5.7 [(−12.7)–(1.4)]
Bifidobacterium
bifidum		0.072 [(−0.05)–(0.2)]−1.9 [(−6.9)–(3.0)]−8.4 [(−16.6)–(−0.2)]
Lactobacillus casei0.16 [(−0.01)–(0.34)]−4.2 [(−11.3)–(2.9)]−9.6 [(−19.6)–(0.4)]
Values are presented as weighted mean difference (95% confidence interval). Statistically significant values are marked in bold. Abbreviations: FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment for insulin resistance; HDL, high-density lipoproteins; LDL, low-density lipoproteins; QUICKI, the quantitative insulin sensitivity check index; TG, triglycerides; VLDL, very-low-density lipoproteins.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yefet, E.; Bar, L.; Izhaki, I.; Iskander, R.; Massalha, M.; Younis, J.S.; Nachum, Z. Effects of Probiotics on Glycemic Control and Metabolic Parameters in Gestational Diabetes Mellitus: Systematic Review and Meta-Analysis. Nutrients 2023, 15, 1633. https://doi.org/10.3390/nu15071633

AMA Style

Yefet E, Bar L, Izhaki I, Iskander R, Massalha M, Younis JS, Nachum Z. Effects of Probiotics on Glycemic Control and Metabolic Parameters in Gestational Diabetes Mellitus: Systematic Review and Meta-Analysis. Nutrients. 2023; 15(7):1633. https://doi.org/10.3390/nu15071633

Chicago/Turabian Style

Yefet, Enav, Liron Bar, Ido Izhaki, Rula Iskander, Manal Massalha, Johnny S. Younis, and Zohar Nachum. 2023. "Effects of Probiotics on Glycemic Control and Metabolic Parameters in Gestational Diabetes Mellitus: Systematic Review and Meta-Analysis" Nutrients 15, no. 7: 1633. https://doi.org/10.3390/nu15071633

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop